Drugs / PAMVAC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02647489 | May 2016 → Nov 2017 | malaria | University Hospital Tuebingen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-01-10 | ExpreS2ion Biotechnologies | Results ExpreS2ion sampublicerar positiva fas I-resultat om placentalt malariavaccin från PlacMalVac-konsortiet expres2ionbio.com ↗
PAMVAC-vaccinet, tillverkat med ExpreS2-plattformen, visades i studien vara säkert, väl tolererat och ha förmåga att framkalla specifika antikroppssvar hos alla studiedeltagare. |
| 2019-01-10 | ExpreS2ion Biotechnologies | Results ExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium expres2ionbio.com ↗
The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-01-10 | ExpreS2ion Biotechnologies | ExpreS2ion sampublicerar positiva fas I-resultat om placentalt malariavaccin från PlacMalVac-konsortiet expres2ionbio.com ↗ |
| 2019-01-10 | ExpreS2ion Biotechnologies | ExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium expres2ionbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAMVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02647489 ↗ |
| Modality | Protein / enzyme biologic | “The PAMVAC vaccine is a VAR2CSA protein-based vaccine” NCT02647489 ↗ |